Sales & Marketing Unlocking impact and growth at times of demerger Pharma and medtech companies have undergone unprecedented growth through aggressive M&A over the
News Lilly's Alzheimer's drug gets UK nod, but no NHS funding The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to be funded by the NHS, according to cost-effectiveness watchdog NI
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.